Therapy (HCV)

IFN Shouldn't Be Given Routinely to HCV RNA Carriers with Normal ALT

Published in Hepatitis Weekly, March 23rd, 1998

Hepatitis C virus RNA carriers with normal alanine aminotransferase (ALT) levels should not be routinely treated with interferon, according to a report from Italy.

"The findings of this pilot study indicate that long-term treatment with low doses of interferon does not lead to eradication or suppression of serum HCV RNA in HCV carriers with persistently normal ALT values," Angelo Sangiovanni and colleagues wrote ("Interferon Alpha Treatment of HCV RNA Carriers with Persistently Normal Transaminase Levels: A Pilot Randomized Controlled Study," Hepatology, March 1998;27(3):853-856).

Certain patients with serum markers of HCV replication (HCV RNA) have...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1998-03-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry